Please provide your email address to receive an email when new articles are posted on . The management of multiple sclerosis has improved considerably over the past decade with broadening of the ...

Among 6 sphingosine-1-phosphate (S1P) receptor modulators evaluated for use in patients with multiple sclerosis (MS), a new meta-analysis shows amiselimod had the highest efficacy. “This network ...

I f you have ulcerative colitis — a type of inflammatory bowel disease (IBD) characterized by stomach pain, fatigue, urgency, and other gut symptoms — you may be familiar with the wide range of ...

May 7, 2012 (New Orleans, Louisiana) — Data on 2 new investigational oral agents with a mechanism similar to that of fingolimod (Gilenya, Novartis) show the drugs were well tolerated and reduced ...

Please provide your email address to receive an email when new articles are posted on . Arena Pharmaceuticals announced that etrasimod, its novel, oral selective sphingosine 1-phosphate receptor ...

Zeposia is the first oral sphingosine-1-phosphate (S1P) receptor modulator to demonstrate benefit in moderate to severe ulcerative colitis in a Phase 3 study PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol ...

Arena Pharmaceuticals, Inc. ARNA received an upgrade from Wall Street on Wednesday as it awaits Phase 2 data for the S1P modulator etrasimod in ulcerative colitis. Wells Fargo's Jim Birchenough ...

The company's etrasimod delivered the goods in mid-stage studies. After its obesity drug Belviq flopped, Arena Pharmaceuticals rebooted its R&D program to focus on other drugs, including etrasimod, a ...

Fred D. Lublin, MD, FAAN, FANA: The sphingosine-1-phosphate receptor modulators are in use now for treating MS [multiple sclerosis]. The first 1 was fingolimod, which was approved in 2010 and we’ve ...

Oral small-molecule therapies are redefining first-line treatment in moderate to severe ulcerative colitis (UC) by offering noninfusion alternatives with rapid onset and high efficacy. Etrasimod, a ...

Treatment with ozanimod (Zeposia) led to clinically meaningful improvement in cognitive processing speed among people with early relapsing multiple sclerosis (RMS), an ad hoc interim analysis of the ...